WO2011022692A3 - Composés de cannabinoïde furanopyridine et procédés d'utilisation afférents - Google Patents

Composés de cannabinoïde furanopyridine et procédés d'utilisation afférents Download PDF

Info

Publication number
WO2011022692A3
WO2011022692A3 PCT/US2010/046222 US2010046222W WO2011022692A3 WO 2011022692 A3 WO2011022692 A3 WO 2011022692A3 US 2010046222 W US2010046222 W US 2010046222W WO 2011022692 A3 WO2011022692 A3 WO 2011022692A3
Authority
WO
WIPO (PCT)
Prior art keywords
furanopyridine
related methods
cannabinoid compounds
compounds
receptors
Prior art date
Application number
PCT/US2010/046222
Other languages
English (en)
Other versions
WO2011022692A2 (fr
Inventor
Bob M. Ii Moore
Steven Gurley
Suni Mustafa
Original Assignee
University Of Tennessee Research Foundation, The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Tennessee Research Foundation, The filed Critical University Of Tennessee Research Foundation, The
Publication of WO2011022692A2 publication Critical patent/WO2011022692A2/fr
Publication of WO2011022692A3 publication Critical patent/WO2011022692A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés d'analogues de cannabinoïde furanopyridine de formule (I). Lesdits composés sont utiles pour modifier l'activité des récepteurs CB1 et CB2 et pour traiter des pathologies médiées par ces récepteurs.
PCT/US2010/046222 2009-08-20 2010-08-20 Composés de cannabinoïde furanopyridine et procédés d’utilisation afférents WO2011022692A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23550209P 2009-08-20 2009-08-20
US61/235,502 2009-08-20

Publications (2)

Publication Number Publication Date
WO2011022692A2 WO2011022692A2 (fr) 2011-02-24
WO2011022692A3 true WO2011022692A3 (fr) 2011-06-16

Family

ID=43605844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/046222 WO2011022692A2 (fr) 2009-08-20 2010-08-20 Composés de cannabinoïde furanopyridine et procédés d’utilisation afférents

Country Status (2)

Country Link
US (1) US8431595B2 (fr)
WO (1) WO2011022692A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
AR084905A1 (es) * 2011-01-21 2013-07-10 Boehringer Ingelheim Int Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US9012456B2 (en) * 2012-02-28 2015-04-21 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100857A1 (fr) * 2001-06-12 2002-12-19 Pharmacia & Upjohn Company Multi-heteroaryles cycliques substitues par quinuclidines pour le traitement de maladies
WO2003022856A1 (fr) * 2001-09-12 2003-03-20 Pharmacia & Upjohn Company 7-aza`2.2.1!bicycloheptanes substitues pour traitement de maladies
WO2003029252A1 (fr) * 2001-10-02 2003-04-10 Pharmacia & Upjohn Company Composes d'heteoraryle fusionne substitues par azabicyclo utiles pour le traitement de maladies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100857A1 (fr) * 2001-06-12 2002-12-19 Pharmacia & Upjohn Company Multi-heteroaryles cycliques substitues par quinuclidines pour le traitement de maladies
WO2003022856A1 (fr) * 2001-09-12 2003-03-20 Pharmacia & Upjohn Company 7-aza`2.2.1!bicycloheptanes substitues pour traitement de maladies
WO2003029252A1 (fr) * 2001-10-02 2003-04-10 Pharmacia & Upjohn Company Composes d'heteoraryle fusionne substitues par azabicyclo utiles pour le traitement de maladies

Also Published As

Publication number Publication date
WO2011022692A2 (fr) 2011-02-24
US20110046176A1 (en) 2011-02-24
US8431595B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
NZ597517A (en) 5-fluoropyrimidinone derivatives
WO2011006886A3 (fr) Composés azole portant un substituant soufré xiv
IN2012DN00692A (fr)
WO2010083322A3 (fr) Compositions fongicides contenant des derives d'hydrazone et du cuivre
WO2009036175A3 (fr) Inhibiteur de f1f0-atpase et procédés associés
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
ZA201006782B (en) Novel p2x7r antagonists and thier use
WO2011022692A3 (fr) Composés de cannabinoïde furanopyridine et procédés d'utilisation afférents
SMT201200017B (it) Nuovi antagonisti P2X7R e il loro uso.
IN2014DN05772A (fr)
NZ597483A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
WO2010102778A3 (fr) 3-aminoisoxazolopyridines substituées en tant que modulateurs de kcnq 2/3
IN2012DN00695A (fr)
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
WO2009120192A3 (fr) Procédé pour la préparation de dérivés d’hétéroaryle benzo-condensés
WO2011073370A3 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
WO2011022679A3 (fr) Composés cannabinoïdes benzofurane et méthodes d'utilisation associées
WO2013062964A3 (fr) Nouveaux modulateurs de trpv3
WO2011022694A3 (fr) Composés cannabinoïdes furanopyrimidine et méthodes d'utilisation associées
MX2012013898A (es) Derivados de n-[(silil trisustituido)metil]-carboxamida fungicidas.
WO2013048989A3 (fr) Composés de pyrazole
TN2012000381A1 (en) 2-aldoximino-5-fluoropyrimidine derivatives
FR2952528B1 (fr) Melange de solvants hydrocarbones.
WO2009078036A3 (fr) Procédé et produit intermédiaire du létrozole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810693

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10810693

Country of ref document: EP

Kind code of ref document: A2